(Q43544469)

24 November 2017

title

The evaluation of multiple surrogate endpoints (English)

1 reference

24 November 2017

Xu J

1

1 reference

24 November 2017

Zeger SL

series ordinal

2

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

24 November 2017

1 reference

24 November 2017

volume

57

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

81-87

1 reference

maintained by WikiProject

24 November 2017

WikiProject Mathematics

0 references

cites work

Marginal regression for repeated binary data with outcome subject to non-ignorable non-response

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

Criteria for the validation of surrogate endpoints in randomized experiments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

The validation of surrogate endpoints in meta-analyses of randomized experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

Meta-analysis for the evaluation of potential surrogate markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

On meta-analytic assessment of surrogate outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

Model-based approaches to analysing incomplete longitudinal and failure time data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

A stochastic model for censored-survival data in the presence of an auxiliary variable

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

Random-effects models for longitudinal data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

Estimating compliance to study medication from serum drug levels: application to an AIDS clinical trial of zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

Estimating the proportion of treatment effect explained by a surrogate marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

Latent variable models with fixed effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

Surrogate endpoints in clinical trials: cardiovascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

A joint model for survival and longitudinal data measured with error

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0006-341X.2001.00081.X

10.1111/J.0006-341X.2001.00081.X

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference